 Home > Biochemistry News > Biotechnology News > GABA receptor allosteric modulator receives priority review qualification, significantly reduces seizure frequency

GABA receptor allosteric modulator receives priority review qualification, significantly reduces seizure frequency

 Last Update: 2021-09-28
 Source: Internet
 Author: User

Tags

fragment based drug discovery

nylon 6 12

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Marinus Pharmaceuticals announced that the U.

This new drug application is based on data support from a phase 3 clinical trial, and a total of 101 patients were enrolled

In terms of safety, ganaxolone was generally well tolerated in this phase 3 trial and showed safety characteristics consistent with previous clinical trials.

CDKL5 deficiency is a serious and rare genetic disease caused by mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene located on the X chromosome

Ganaxolone is an under-researched gender modulator targeting GABAA receptors.

Reference materials:

[1] Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.